BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36208048)

  • 21. [CK7+/CD117- low grade oncocytic tumor of the kidney: a clinicopathological analysis].
    Bai YF; Chang CD; Wang B; Zhao M; Teng XD
    Zhonghua Bing Li Xue Za Zhi; 2022 Oct; 51(10):976-980. PubMed ID: 36207909
    [No Abstract]   [Full Text] [Related]  

  • 22. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm.
    Chen YB; Mirsadraei L; Jayakumaran G; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE
    Am J Surg Pathol; 2019 Jan; 43(1):121-131. PubMed ID: 30303819
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-Grade Oncocytic Tumor of Kidney (CK7-Positive, CD117-Negative): Incidence in a single institutional experience with clinicopathological and molecular characteristics.
    Kravtsov O; Gupta S; Cheville JC; Sukov WR; Rowsey R; Herrera-Hernandez LP; Lohse CM; Knudson R; Leibovich BC; Jimenez RE
    Hum Pathol; 2021 Aug; 114():9-18. PubMed ID: 33961838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chromophobe renal cell carcinoma: current and controversial issues.
    Moch H; Ohashi R
    Pathology; 2021 Jan; 53(1):101-108. PubMed ID: 33183792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others.
    Li H; Argani P; Halper-Stromberg E; Lotan TL; Merino MJ; Reuter VE; Matoso A
    Am J Surg Pathol; 2023 Nov; 47(11):1267-1273. PubMed ID: 37661807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-grade oncocytic tumor (LOT) - a new renal entity ready for a prime time: An updated review.
    Mansoor M; Siadat F; Trpkov K
    Histol Histopathol; 2022 May; 37(5):405-413. PubMed ID: 35156688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low-Grade Oncocytic Tumor: Report of Two Cases of An Emerging Entity in the Spectrum of Oncocytic Renal Neoplasms.
    Sharma D; Pai T; Prakash G; Desai S; Menon S
    Turk Patoloji Derg; 2022; 38(2):162-166. PubMed ID: 34514579
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sporadic oncocytic tumors with features intermediate between oncocytoma and chromophobe renal cell carcinoma: comprehensive clinicopathological and genomic profiling.
    Liu YJ; Ussakli C; Antic T; Liu Y; Wu Y; True L; Tretiakova MS
    Hum Pathol; 2020 Oct; 104():18-29. PubMed ID: 32673684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
    Kwiatkowski DJ; Choueiri TK; Fay AP; Rini BI; Thorner AR; de Velasco G; Tyburczy ME; Hamieh L; Albiges L; Agarwal N; Ho TH; Song J; Pignon JC; Barrios PM; Michaelson MD; Van Allen E; Krajewski KM; Porta C; Pal S; Bellmunt J; McDermott DF; Heng DYC; Gray KP; Signoretti S
    Clin Cancer Res; 2016 May; 22(10):2445-2452. PubMed ID: 26831717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background.
    Pivovarcikova K; Alaghehbandan R; Vanecek T; Ohashi R; Pitra T; Hes O
    Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. TSC/MTOR -associated Eosinophilic Renal Tumors Exhibit a Heterogeneous Clinicopathologic Spectrum : A Targeted Next-generation Sequencing and Gene Expression Profiling Study.
    Xia QY; Wang XT; Zhao M; He HY; Fang R; Ye SB; Li R; Wang X; Zhang RS; Lu ZF; Ma HH; Wang ZY; Rao Q
    Am J Surg Pathol; 2022 Nov; 46(11):1562-1576. PubMed ID: 35980750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases.
    Petersson F; Gatalica Z; Grossmann P; Perez Montiel MD; Alvarado Cabrero I; Bulimbasic S; Swatek A; Straka L; Tichy T; Hora M; Kuroda N; Legendre B; Michal M; Hes O
    Virchows Arch; 2010 Apr; 456(4):355-65. PubMed ID: 20300772
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Morphological and Molecular Study of Hybrid Oncocytic/Chromophobe Tumor of the Kidney Associated with Sporadic Renal Oncocytosis and Chronic B-Cell Lymphocytic Leukemia: The Possible Contribution of Lymphoma to Renal Oncocytosis.
    Idoate MA; Trigo I; Saenz de Zaitigui J; Pérez-Pérez M; Ríos JJ
    Pathobiology; 2021; 88(4):313-322. PubMed ID: 33882490
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from China.
    Guo Q; Liu N; Wang F; Guo Y; Yang B; Cao Z; Wang Y; Wang Y; Zhang W; Huang Q; Zhao W; Liu C; Qu T; Li L; Cao L; Ren D; Meng B; Qi L; Wang C; Cao W
    Virchows Arch; 2021 Mar; 478(3):449-458. PubMed ID: 32918598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. "High-grade oncocytic renal tumor": morphologic, immunohistochemical, and molecular genetic study of 14 cases.
    He H; Trpkov K; Martinek P; Isikci OT; Maggi-Galuzzi C; Alaghehbandan R; Gill AJ; Tretiakova M; Lopez JI; Williamson SR; Montiel DP; Sperga M; Comperat E; Brimo F; Yilmaz A; Pivovarcikova K; Michalova K; Slouka D; Prochazkova K; Hora M; Bonert M; Michal M; Hes O
    Virchows Arch; 2018 Dec; 473(6):725-738. PubMed ID: 30232607
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-existence of ESC-RCC, EVT, and LOT as synchronous and metachronous tumors in six patients with multifocal neoplasia but without clinical features of tuberous sclerosis complex.
    Lerma LA; Schade GR; Tretiakova MS
    Hum Pathol; 2021 Oct; 116():1-11. PubMed ID: 34153307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.
    Lim SM; Park HS; Kim S; Kim S; Ali SM; Greenbowe JR; Yang IS; Kwon NJ; Lee JL; Ryu MH; Ahn JH; Lee J; Lee MG; Kim HS; Kim H; Kim HR; Moon YW; Chung HC; Kim JH; Kang YK; Cho BC
    Oncotarget; 2016 Mar; 7(9):10547-56. PubMed ID: 26859683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Somatic Mutations in TSC1 and TSC2 Cause Focal Cortical Dysplasia.
    Lim JS; Gopalappa R; Kim SH; Ramakrishna S; Lee M; Kim WI; Kim J; Park SM; Lee J; Oh JH; Kim HD; Park CH; Lee JS; Kim S; Kim DS; Han JM; Kang HC; Kim HH; Lee JH
    Am J Hum Genet; 2017 Mar; 100(3):454-472. PubMed ID: 28215400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Do we need an updated classification of oncocytic renal tumors? : Emergence of low-grade oncocytic tumor (LOT) and eosinophilic vacuolated tumor (EVT) as novel renal entities.
    Hes O; Trpkov K
    Mod Pathol; 2022 Sep; 35(9):1140-1150. PubMed ID: 35273336
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases.
    Tjota MY; Sharma A; Wanjari P; Fitzpatrick C; Segal J; Antic T
    Hum Pathol; 2023 Apr; 134():124-133. PubMed ID: 36592877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.